Nanobiotix is a clinical-stage biotechnology company that has developed a novel physics-based approach to cancer treatment. Their lead product, NBTXR3, is composed of hafnium oxide nanoparticles that, when injected into a tumor and activated by radiotherapy, magnify the energy dose, leading to greater tumor destruction without increasing damage to surrounding healthy tissue.
Paris
2003
51–200
